Synexus recruits 20 percent of patients in Crestor Jupiter Study, UKrecruits With only eight of its 14 hub sites Synexus and randomized more than 2,740 of the 15,000 patients in AstraZeneca’s Crestor Jupiter study are involved in cardiovascular disease.The study was stopped early, there is clear evidence of a reduction in cardiovascular morbidity and mortality was carried out in 1,200 locations in 26 countries.The Synexus model with full-time investigators at its hub sites by reducing the cost of running clinical trials that monitor a negotiation and contract instead of hundreds and a handful of websites.Synexus is planning to expand in the U.S.
– Lower maternal weight, with HIV-positive women with a body weight of six % less than women who tested negative – investigated a possible indication that HIV was in the early stages of AIDS progress for women.Zaffanello M, Brugnara M, Cocchetto M, Fedrizzi M, Fano V. Scand J Urol Nephrol. 2008 May 8:1-7. Epub ahead of print.1080/00365590802092006Narrated by UroToday.com Medical Editor Pasquale Casale, MDUroToday – the sole urology site to original content by global urological key opinion leaders actively engaged in the written clinical practices.
Over Decision ResourcesDecision Resources a world leader of market research being assist publications, advisory und Consulting on client figure policy, allocate resources and manage their chosen markets. , high – Resources be a Decision Resources.